BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20801048)

  • 1. Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI.
    Giorgioni G; Ambrosini D; Vesprini C; Hudson A; Nasuti C; Di Stefano A; Sozio P; Ciampi O; Costa B; Martini C; Carrieri A; Carbonara G; Enzensperger C; Pigini M
    Bioorg Med Chem; 2010 Oct; 18(19):7085-91. PubMed ID: 20801048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
    Boronat MA; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study.
    Ugedo L; Pineda J; Ruiz-Ortega JA; Martín-Ruiz R
    Br J Pharmacol; 1998 Dec; 125(8):1685-94. PubMed ID: 9886760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoradiographic localisation of [3H]2-BFI imidazoline I2 binding sites in mouse brain.
    MacInnes N; Handley SL
    Eur J Pharmacol; 2005 Jun; 516(2):139-44. PubMed ID: 15925361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo.
    Sastre-Coll A; Esteban S; Miralles A; Zanetti R; García-Sevilla JA
    Neurosci Lett; 2001 Mar; 301(1):29-32. PubMed ID: 11239709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.
    Bour S; Iglesias-Osma MC; Marti L; Duro P; Garcia-Barrado MJ; Pastor MF; Prévot D; Visentin V; Valet P; Moratinos J; Carpéné C
    Eur J Pharmacol; 2006 Dec; 552(1-3):20-30. PubMed ID: 17056035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) induces region-specific increases in [3H]2-BFI binding to rat central imidazoline I2 sites.
    MacInnes N; Handley SL
    Neurosci Lett; 2004 Jun; 363(1):11-3. PubMed ID: 15157985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-ols.
    Kornicka A; Saczewski F; Tyacke RJ; Hudson AL; Nutt DJ
    Acta Pol Pharm; 2005; 62(6):497-502. PubMed ID: 16583991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
    Miralles A; Esteban S; Sastre-Coll A; Moranta D; Asensio VJ; García-Sevilla JA
    Eur J Pharmacol; 2005 Aug; 518(2-3):234-42. PubMed ID: 16061219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazoline binding sites (IBS) profile modulation: key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues.
    Gentili F; Bousquet P; Brasili L; Dontenwill M; Feldman J; Ghelfi F; Giannella M; Piergentili A; Quaglia W; Pigini M
    J Med Chem; 2003 May; 46(11):2169-76. PubMed ID: 12747788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
    Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
    Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.
    Mewshaw RE; Kavanagh J; Stack G; Marquis KL; Shi X; Kagan MZ; Webb MB; Katz AH; Park A; Kang YH; Abou-Gharbia M; Scerni R; Wasik T; Cortes-Burgos L; Spangler T; Brennan JA; Piesla M; Mazandarani H; Cockett MI; Ochalski R; Coupet J; Andree TH
    J Med Chem; 1997 Dec; 40(26):4235-56. PubMed ID: 9435894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria.
    Radwanska A; Dlugokecka J; Wasilewski R; Kaliszan R
    J Physiol Pharmacol; 2009 Mar; 60(1):131-42. PubMed ID: 19439815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
    Carpéné C; Collon P; Remaury A; Cordi A; Hudson A; Nutt D; Lafontan M
    J Pharmacol Exp Ther; 1995 Feb; 272(2):681-8. PubMed ID: 7853182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of intracellular Ca
    Siemian JN; Qiu Y; Zhang Y; Li JX
    Psychopharmacology (Berl); 2017 Nov; 234(22):3299-3307. PubMed ID: 28825118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.